Argenx Buys Forte

Forte Biosciences announced that it will be acquired by Belgian‑Dutch immunology firm argenx for $77 per share in a fully cash‑priced, all‑cash transaction valued at approximately $2.2 billion. The offer represents a premium of roughly 40 % to Forte’s previous closing price and about 86 % to its volume‑weighted average price as of July 9, following the release of positive Phase 1b data for its lead candidate FB102 in both vitiligo and celiac disease. argenx will launch a tender offer through a wholly owned subsidiary, with the transaction expected to close in the third quarter of 2026 using argenx’s existing cash reserves.